Mark Soltz
23 posts
🚨 CANCER SCAM EXPOSED: “Chemo Destroys the Very Cells That Could Save You.” 🚨 Dr. Patrick Soon-Shiong just dropped a bombshell: 🧬 “Chemo. Radiation. Even Temodol — they wipe out your natural killer cells, your body’s best defense against cancer.” 💥 One radiation dose can shut down your immune response for a YEAR. 💥 Steroids, chemo & Big Pharma’s drugs? They’re crippling your only shield. But the truth is out now—and it’s being called "Bio-Shield Therapy." A single injection that reawakens your cancer-killing cells. ✅ Patients with bladder cancer are disease-free 10+ years ✅ No toxic chemo or radiation ✅ Could treat long COVID, HIV & even sepsis ❌ Biden’s FDA blocked this. ❌ Big Pharma fought to bury it. Why? Because you can't patent the immune system God gave you. 🔥 The era of poisoning the body to “save it” is OVER. 🔥 The future of medicine is already here. 📢 FULL STORY in Cancer Decoded. Follow now to learn how we end the suffering—and save millions. @drpatrick
Today, HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced a new pledge from top health insurers to fix the broken prior authorization system. UnitedHealthcare, Aetna, Cigna, Humana, Kaiser Permanente, Blue Cross Blue Shield, and others signed on. Together, they cover over 80% of U.S. patients. Insurers committed to six major changes: 1. Use standardized electronic prior authorization tools (FHIR-based APIs). 2. Cut the number of services requiring prior auth by January 1, 2026. 3. Guarantee 90-day continuity when patients switch insurers. 4. Improve transparency around decisions and appeals. 5. Provide real-time responses for most requests by 2027. 6. Require clinical review for all denials. The pledge is voluntary, but CMS says regulation will follow if insurers don’t deliver.
$IBRX Every once in a lifetime, a company emerges seemingly out of nowhere that not only redefines its industry but also becomes its new market leader. The old leaders are relegated to becoming "also participating in this industry". We saw it 30 years ago with Amazon, 20 years ago with Tesla, and recently with Palantir. And now we’re seeing it for the first time ever in the pharmaceutical industry with @ImmunityBio. While pharma companies have traditionally focused on treatments for specific illnesses, ImmunityBio went another way. They believed your body can heal itself from most illnesses if your immune system works fine. They realized that when your immune system fails, it opens the door to serious illnesses like cancer, HIV, sepsis, pneumonia—you name it! So they developed therapies to supercharge the immune system, starting with cancer but with the potential to tackle nearly every disease. Like Amazon, which began with books and now sells everything, IBRX is starting with cancer but could cure almost everything. Amazon, Tesla, and Palantir had sky-high valuations early on and grew into them. Yet ImmunityBio, with its revolutionary approach, still sits at a laughably low valuation—barely scratching $2B when it should be at least $10B by now. The stock has just now broken a multi-year downtrend and is finally starting its multi-year move upwards. And let’s talk leadership. Palantir has rockstar CEO Alex Karp, but pharma has never seen a visionary like @drpatrick. He’s the only rockstar CEO in pharma history, blending science, strategy, and bold bets to redefine medicine. Palantir, founded in 2003, took nearly 20 years to dominate software and AI. ImmunityBio, founded in 2014, carries Dr. Soon-Shiong’s lifelong vision to revolutionize healthcare. Just as Amazon left Barnes & Noble in the dust, IBRX could outpace pharma giants like Pfizer, Roche, Johnson & Johnson, and Merck, relegating them to mere participants in a new era of medicine. IBRX isn’t just a company; it’s the future of healthcare.
